Phase 1 Study of Anti-glycation Agent GLY-230 in Healthy Subjects

Phase 1 Study of Anti-glycation Agent GLY-230

To test the safety of GLY-230 and to evaluate how long drug stays in blood after taking it by mouth.

Inclusion Criteria:

• Men age 18-55
• Negative drug screen
• Normal EKG, clinical chemistries, CBC, urinalysis, and
• Give written informed consent

Exclusion Criteria:

• Active concomitant serious medical or surgical disease,
• Hepatic or renal laboratory values above reference range, ise of other experimental drug within previous 30 days